On the eve of this year’s ASCO annual meeting, Pfizer said it is teaming up with China’s Innovent Biologics to advance a portfolio of 12 early-stage antibody-drug conjugates and multi-specific antibodies in a deal that could be worth up to $10.5 billion.
On the eve of this year’s ASCO annual meeting, Pfizer said it is teaming up with China’s Innovent Biologics to advance a portfolio of 12 …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Pfizer, Innovent strike $10B cancer drug deal
Pfizer and Innovent Biologics sign $10.5B cancer drug deal
Pfizer, Innovent Biologics sign $10.5bn cancer drug development deal
Pfizer Strikes Up To $10.5 Billion Deal With Innovent Biologics - Pfizer (NYSE:PFE)
China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials
Pfizer inks up to $10.5 billion deal with China’s Innovent Biologics
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
L'accordo con Innovent Biologics fa tenere a Pfizer un piede negli Usa e l'altro in Cina - Startmag
Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational…
The U.S. pharma giant will pay $650 million upfront to China's Innovent Biologics to co-develop 12 early-stage oncology programs
Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5bn for the research and…
Pfizer and Innovent Biologics sign a $10.5 billion cancer drug deal to develop 12 oncology programs globally.
The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer.
Pfizer Inc. and China’s Innovent Biologics Inc. signed a global agreement worth as much as $10.5 billion to develop cancer drugs.
